You are here

Cancer Res DOI:10.1158/0008-5472.CAN-17-1701

Genomic Activation of Reveals a Candidate Therapeutic Axis in Bladder Cancer.

Publication TypeJournal Article
Year of Publication2017
AuthorsGoldstein, JT, Berger, AC, Shih, J, Duke, FF, Furst, L, Kwiatkowski, DJ, Cherniack, AD, Meyerson, M, Strathdee, CA
JournalCancer Res
Volume77
Issue24
Pages6987-6998
Date Published2017 12 15
ISSN1538-7445
KeywordsAnimals, Cell Line, Tumor, CRISPR-Cas Systems, Gene Amplification, Gene Expression Profiling, Gene Expression Regulation, Neoplastic, Humans, Microarray Analysis, Molecular Targeted Therapy, Mutation, PPAR gamma, Transcriptome, Urinary Bladder Neoplasms
Abstract

The gene encoding the nuclear receptor PPARγ is activated in bladder cancer, either directly by gene amplification or mutation, or indirectly by mutation of the gene, which encodes the heterodimeric partner of PPARγ. Here, we show that activating alterations of or lead to a specific gene expression signature in bladder cancers. Reducing PPARG activity, whether by pharmacologic inhibition or genetic ablation, inhibited proliferation of PPARG-activated bladder cancer cells. Our results offer a preclinical proof of concept for PPARG as a candidate therapeutic target in bladder cancer. .

DOI10.1158/0008-5472.CAN-17-1701
Pubmed

http://www.ncbi.nlm.nih.gov/pubmed/28923856?dopt=Abstract

Alternate JournalCancer Res.
PubMed ID28923856
PubMed Central IDPMC5835321
Grant ListR35 CA197568 / CA / NCI NIH HHS / United States